Tyra Biosciences, Inc clinical trial pipeline

4 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 4 with minor changes only.

1. Minor

   SURF201 · Anti-Tumor Activity of TYRA-200 in Advanced…SURF201 · Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations

   Primary completion pushed from Sep 2026 to Mar 2027

   Tyra Biosciences, Inc·Phase 1· NCT06160752· Registry history of NCT06160752 on ClinicalTrials.gov (opens the registry)

   Oct 14, 2026

2. Minor

   SURF303 · 2A/B Efficacy and Safety of Dabogratinib · Low Grade…SURF303 · 2A/B Efficacy and Safety of Dabogratinib · Low Grade Upper Tract Urothelial Carcinoma

   Enrollment increased: 230 → 285 participants

   Also in this update: Interventions modified; Trial arms changed: 3 → 2; and 1 more change in the last 30 days

   Tyra Biosciences, Inc·Phase 2· NCT07265947· Registry history of NCT07265947 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

3. Minor

   SURF431 · Anti-Tumor Activity of TYRA-430 in Advanced…SURF431 · Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations

   Enrollment increased: 100 → 125 participants

   Tyra Biosciences, Inc·Phase 1· NCT06915753· Registry history of NCT06915753 on ClinicalTrials.gov (opens the registry)

   Sep 23, 2026

4. Minor

   SURF302 · TYRA-300 · FGFR3 Altered Low Grade, Intermediate…SURF302 · TYRA-300 · FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

   Interventions modified

   Tyra Biosciences, Inc·Phase 2· NCT06995677· Registry history of NCT06995677 on ClinicalTrials.gov (opens the registry)

   Sep 29, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.